Dr. Martens (LON:DOCS) Insider Ije Nwokori Acquires 238 Shares of Stock

Dr. Martens plc (LON:DOCS) insider Ije Nwokori acquired 238 shares of the stock in a transaction dated Wednesday, November 11th. The stock was bought at an average price of GBX 63 per share, for a total transaction of £149.94.

Ije Nwokori also recently made the following trade(s):

• On Friday, October 16th, Ije Nwokori sold 209,160 shares of Dr. Martens stock. The stock was sold at an average price of GBX 69, for a total value of £144,320.40.
• On Monday, October 12th, Ije Nwokori bought 220 shares of Dr. Martens stock. The shares were bought at an average price of GBX 68 per share, with a total value of £149.60.
• On Friday, September 11th, Ije Nwokori purchased 232 shares of Dr. Martens stock. The stock was bought at an average cost of GBX 65 per share, for a total transaction of £150.80.

Dr. Martens Stock Performance

Shares of LON:DOCS opened at GBX 53.10 on Thursday. The business’s fifty day moving average price is GBX 67.13 and its two-hundred day moving average price is GBX 69.53. Dr. Martens plc has a fifty-two week low of GBX 52.10 and a fifty-two week high of GBX 90. The stock has a market capitalization of £508.31 million, a price-to-earnings ratio of 22.12, a price-to-earnings-growth ratio of 6.40 and a beta of 0.26. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13.

Dr. Martens (LON:DOCS) last issued its quarterly earnings data on Thursday, November 12th. The company reported GBX (1) earnings per share (EPS) for the quarter. The company had revenue of £290.40 million for the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. As a group, analysts predict that Dr. Martens plc will post 2.58 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Berenberg Bank reissued a “buy” rating and set a GBX 110 price target on shares of Dr. Martens in a report on Friday, October 9th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of GBX 105.

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.